95
Anticoagulation Reversal May 11, 2013

Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Embed Size (px)

DESCRIPTION

Patient Care Medical Knowledge Practice-Based Learning and Improvement Interpersonal and Communication Skills Professionalism Systems-Based Practice ACGME Competencies Addressed

Citation preview

Page 1: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Anticoagulation Reversal

May 11, 2013

Page 2: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Objectives

• Develop an approach for treating patients with iatrogenic coagulopathy

• Understand recent changes in STEMI care• Review the ICH treatment protocol

Page 3: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Patient Care

Medical Knowledge

Practice-Based Learning and ImprovementInterpersonal and Communication Skills

ProfessionalismSystems-Based Practice

ACGME Competencies Addressed

Page 4: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 5: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Tissue factor pathway

Contact activation pathway

Page 6: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Tissue factor pathway

Contact activation pathway

Haemophilia A

Haemophilia B

Page 7: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the mechanism of action of warfarin?

Page 8: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the mechanism of action of warfarin?

• Inhibits Vitamin K epoxide reductase

Page 9: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

The American College of Chest Physicians guideline for the reversal of anticoagulation

therapy (8th ed.).

Page 10: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Vitamin K epoxide reductase

Page 11: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What clotting factors are affected by warfarin?

Page 12: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 13: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

78 year old with history of PE presents with weakness and UTI. INR = 8.

Page 14: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 15: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

58 year old with history of atrial fibrillation and HTN on warfarin presents with ICH. GCS = 6 and INR = 4.

Page 16: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 17: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

67 year old with pmh atrial fibrillation on warfarin presents with brisk nose bleed. INR = 6.

Page 18: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the universal donor FFP type?

Page 19: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the universal donor FFP type?

• AB

Page 20: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

One unit plasma replaced what percent of clotting factors?

Page 21: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

One unit plasma replaced what percent of clotting factors?

• 2.5%

Page 22: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How low can you get the INR with FFP?

Page 23: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How low can you get the INR with FFP?

• 1.5

Page 24: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Name two problems with FFP

Page 25: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Name two problems with FFP

• Time• Volume

Page 26: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

PCCWhat types of PCC are there?

Page 27: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

PCCWhat types of PCC are there?

• 3 factor• 4 factor

Page 28: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

3 Factor PCCProfilnine

• II• IX• X• Very small amount of VII

Page 29: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 30: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 31: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Kcentra

• 4F-PCC– II– VII– IX– X

Page 32: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 33: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 34: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the mechanism of action of Xabans?

Page 35: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the mechanism of action of Xabans?

• Xa inhibitor

Page 36: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Xabans-rivaroxaban (Xarelto)

Page 37: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How would you treat major bleeding in someone on Rivaroxaban?

Page 38: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How would you treat major bleeding in someone on Rivaroxaban?

• PCC (?)

Page 39: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

XabansRivaroxaban (Xarelto)

• Xa inhibitors• PCC

Page 40: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Dabigatran (Pradaxa)

• What is mechanism of action?

Page 41: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

dabigatran(Pradaxa)

Page 42: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Dabigatran (Pradaxa)

• Renal metabolism• Can not be monitored• Normal PTT helpful, but abnormal PTT not

helpful• PCC?• FEIBA (Factor eight inhibitor bypass activity)?

Page 43: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the mechanism of action of heparin?

Page 44: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Heparin

• Activates Antithrombin III

Page 45: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

HeparinActivates Antithrombin III

Page 46: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

You have a patient in the ED with a non-STEMI. You put them on heparin. They develop a severe headache and you diagnose an ICH.

What do you do?

Page 47: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How do you treat a patient with major bleeding on heparin?

• Protamine

Page 48: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

LMW Heparin

Page 49: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Low Molecular Weight Heparin

• Blocks Xa• Protamine causes partial reversal

Page 50: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Tissue Plasminogen Activator

• Cryoprecipitate• Platelets• FFP• Heparin reversal if on heparin

Page 51: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

TissuePlasminogenActivator

Page 52: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 53: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Safest central line site for a patient with an elevated INR

Page 54: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Safest central line site for a patient with an elevated INR

• Internal Jugular

Page 55: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What should the INR be before dong an LP?

Page 56: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What should the INR be before dong an LP?

• 1.5

Page 57: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

ICH Protocol

Page 58: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Antiplatelet Therapy

• Cyclooxygenase Inhibitors• P2Y12 receptor antagonists (ADP)• GP Iib/IIIa antagonists

Page 59: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 60: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 61: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How does aspirin work?

Page 62: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How does aspirin work?

• Irreversible inhibition of COX-1 (cyclooxygenase 1)

• Blocks TXA2 production (thromboxane A2)?

Page 63: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 64: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 65: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Treatment of major bleeding for a patient on aspirin?

Page 66: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Treatment of major bleeding for a patient on aspirin?

• Platelet transfusion• DDAVP (analog of vasopressin)

Page 67: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

1 unit of single donor (pheresis) platelets = how many units of pooled donors?

Page 68: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

1 unit of single donor (pheresis) platelets = how many units of pooled donors?

6-10

Page 69: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is Aggrenox?

Page 70: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is Aggrenox?

• Aspirin• Dipyridamole

Page 71: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 72: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the half life of clopidogrel?

Page 73: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What is the half life of clopidogrel?

• 6-7 hours• Binds P2Y12 receptor irreversibly

Page 74: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 75: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

P2Y12 Inhibitors

• Clopidegrel (Plavix)• Prasugrel• Ticagrelor

Page 76: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What are two drug classes you may want to avoid for patients on clopidogrel?

Page 77: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What are two drug classes you may want to avoid for patients on clopidogrel?

• PPIs• Macrolides

Page 78: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Which P2Y12 inhibitor should you avoid in a patient with a history of TIA or CVA

• Prasugrel

Page 79: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 80: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How do you treat a patient on clopidogrel with major bleeding?

Page 81: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

How do you treat a patient on clopidogrel with major bleeding?

• Platelets – 2 units• DDAVP?• fFVII?

Page 82: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

GPIIbIIIa Inhibitor

• Abciximab (ReoPro)• Triofiban (Aggrastat)• Eptifibatide (Integrillin)

Page 83: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in
Page 84: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

STEMI Protocol

Page 85: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What antiplatelet is given to STEMI patients at SJH and MMC?

Page 86: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What antiplatelet is given to STEMI patients at SJH and MMC?

Ticagrelor (Brilinta)

Page 87: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Ticagrelor

• "David Griffen" wrote: Frank, Could you please refresh my memory - what was the rationale regarding replacing Plavix with ticagrelor for the STEMI orders?

• It's proven clinical superiority in head-to-head ACS clinical trial (PLATO) for which it has received a Class I recommendation in the 2013 ACC/AHA STEMI guidelines and is preferred over plavix in the 2012 European STEMI guidelines.

Page 88: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What has just replaced heparin in the STEMI (Star 80) at MMC?

Page 89: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

What has just replaced heparin in the STEMI (Star 80) at MMC?

• Angiomax (bivalirudin)• Revisable inhibitor of thrombin• it is a synthetic congener of the naturally

occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis

Page 90: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Anticoagulant Therapy to Support Primary PCI

For patients with STEMI undergoing primary PCI, the following supportive anticoagulant regimens are recommended:

• UFH, with additional boluses administered as needed to maintain therapeutic activated clotting time levels, taking into account whether a GP IIb/IIIa receptor antagonist has been administered; or

• Bivalirudin with or without prior treatment with UFH.

I IIa IIb III

I IIa IIb III

Page 91: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Anticoagulant Therapy to Support Primary PCI

In patients with STEMI undergoing PCI who are at high risk of bleeding, it is reasonable to use bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist.

Fondaparinux should not be used as the sole anticoagulant to support primary PCI because of the risk of catheter thrombosis.

I IIa IIb III

I IIa IIb III

Harm

Page 92: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Why I get confused

• Aggrenox• Angiomax• Aggrastat

Page 93: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Objectives

• Learn strategies for treating patients with iatrogenic coagulopathy

• Understand recent changes in STEMI care• Review the ICH treatment protocol

Page 94: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

• Dr. J. Wall on coagulopathy in trauma June 6th.

Page 95: Anticoagulation Reversal May 11, 2013. Objectives Develop an approach for treating patients with iatrogenic coagulopathy Understand recent changes in

Recommended preparation

• CAEP 2012 Annual ConferenceJune 3- June 6, 2012– What's New in the Management of the Massively

Bleeding Trauma PatientDr. Sandro Rizoli